Clinical

The panelists examined how the scarcity of mental health specialists creates a cascading effect on care capacity, where patients who do not respond to initial primary care treatment face an increasingly narrow pool of expert clinicians equipped to manage complex, refractory cases.

Real-world DME care falls short from missed anti-VEGF loading; sustained delivery, neuroprotection, and better primary care coordination promise gains.

Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.

Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.

Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

Replacing chemotherapy with blinatumomab improved event-free survival and reduced toxicity in high-risk pediatric ALL, data show.

The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Although smaller studies have highlighted CAR T differences in access and outcomes, new research shows the full extent of the issue.

Post-AKI care requires tiered monitoring and medication holds, yet awareness gaps persist among patients and clinicians, said Thai Dang, MD.

Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia.

The bispecific T-cell engager could fulfill an unmet need among patients with mantle cell lymphoma who progress after treatment with a BTK inhibitor.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

SC isatuximab via OBI earned EU approval in multiple myeloma, showing less than 1% IRR rates, strong reliability, and potential for at-home use.

A thriving gut microbiome is associated with better clinical outcomes after CAR T-cell therapy for lymphoma and myeloma.

Shannon L. Maude, MD, PhD, highlighted promising long-term disease-free survival and MRD negativity with tisagenleucel in high-risk pediatric ALL.

New evidence links oxidative stress to vitiligo autoimmunity, highlighting antioxidant plus phototherapy or JAK combinations for better repigmentation.

As GLP-1 approvals expand into new indications, claims data reveal most treated patients already qualify under multiple indications.

Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML.

Long-term LUNA3 data showed rilzabrutinib delivered durable platelet responses, reduced bleeding and fatigue, and maintained safety in ITP.

In this episode, 'Operationalizing RRFL Care: Sequencing Therapies, Managing REMS, and the Role of R² in Practice,' the pharmacist Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions: 1. From a pharmacy operations standpoint, how do you characterize the current treatment landscape for relapsed or refractory follicular lymphoma (RRFL), and how has the growing number of available agents affected formulary management and operational planning at your institution? 2. Lenalidomide plus rituximab has been a commonly used combination in RRFL. How have you positioned this regimen in your own practice, and what have been its strengths and limitations in your experience?